Cite
5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
MLA
El-Adl, Khaled, et al. “5-(4-Methoxybenzylidene)Thiazolidine-2,4-Dione-Derived VEGFR-2 Inhibitors: Design, Synthesis, Molecular Docking, and Anticancer Evaluations.” Archiv Der Pharmazie, vol. 353, no. 9, Sept. 2020, p. e2000079. EBSCOhost, https://doi.org/10.1002/ardp.202000079.
APA
El-Adl, K., Sakr, H., Nasser, M., Alswah, M., & Shoman, F. M. A. (2020). 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations. Archiv Der Pharmazie, 353(9), e2000079. https://doi.org/10.1002/ardp.202000079
Chicago
El-Adl, Khaled, Helmy Sakr, Mohamed Nasser, Mohamed Alswah, and Fatma M A Shoman. 2020. “5-(4-Methoxybenzylidene)Thiazolidine-2,4-Dione-Derived VEGFR-2 Inhibitors: Design, Synthesis, Molecular Docking, and Anticancer Evaluations.” Archiv Der Pharmazie 353 (9): e2000079. doi:10.1002/ardp.202000079.